<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085148</url>
  </required_header>
  <id_info>
    <org_study_id>15906</org_study_id>
    <secondary_id>2013-003579-36</secondary_id>
    <nct_id>NCT02085148</nct_id>
  </id_info>
  <brief_title>A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</brief_title>
  <official_title>A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose escalation phase of the study :&#xD;
&#xD;
      To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose&#xD;
      (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off&#xD;
      schedule in repeating cycles of 28 days in pediatric subjects with solid malignant tumors&#xD;
      recurrent or refractory to standard therapy. To characterize the pharmacokinetics (PK) of&#xD;
      regorafenib The dose escalation phase of the study has been completed.&#xD;
&#xD;
      Expansion phase:&#xD;
&#xD;
      To define the safety profile, MTD and the RP2D of regorafenib administered orally in&#xD;
      combination with backbone chemotherapy (vincristine and irinotecan) at relapse in pediatric&#xD;
      subjects with rhabdomyosarcoma (RMS) and other solid malignant tumors recurrent or refractory&#xD;
      to standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Expansion Phase of the study:&#xD;
&#xD;
      Subjects must have relapsed/refractory RMS or a solid malignant tumor (Ewing sarcoma,&#xD;
      hepatoblastoma, neuroblastoma and Wilms tumor).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 11, 2014</start_date>
  <completion_date type="Anticipated">December 28, 2024</completion_date>
  <primary_completion_date type="Actual">May 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Maximum Tolerated Dose</measure>
    <time_frame>approximately after 21 months</time_frame>
    <description>MTD is defined as the dose level at which none or 1 of 6 participants experiences dose-limiting toxicity (DLT), when at least 2 of 3-6 participants experience a DLT at the next highest dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Recommended Phase II Dose</measure>
    <time_frame>approximately after 21 months</time_frame>
    <description>In order to establish a RP2D, the MTD cohort will be expanded to have at least 12 evaluable subjects to confirm the RP2D. It is expected that at least 15 subjects evaluable for DLTs will be necessary to establish the RP2D of the combination&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Dose escalation phase:approximately after 21 months; Expansion Phase: approximately after 21 months</time_frame>
    <description>Individual listings of adverse events will be provided. The incidence of treatment-emergent adverse events and drug-related adverse events, respectively, will be summarized by worst NCI-CTCAE v 4.0 grade and by dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md based on nominal dosing</measure>
    <time_frame>Dose escalation phase:Cycle 1 Day 1, Day 15 and Day 21</time_frame>
    <description>Dose escalation phase has been completed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Dose escalation phase: approximately 21 months; Expansion phase: approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Dose escalation phase: approximately 21 months; Expansion phase: approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: tumor assessment by RECIST v. 1.1</measure>
    <time_frame>Dose escalation phase: approximately 21 months; Expansion phase: approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Taste and texture questionnaire of the regorafenib formulations</measure>
    <time_frame>Dose escalation phase: Cycle 1; Expansion phase:Concomitant: Cycle 1 Day 1;Sequential: Cycle 1 Day 8</time_frame>
    <description>Expansion phase Dose escalation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24)md based on nominal dosing</measure>
    <time_frame>Expansion Phase:Cycle 1 Day1, Day 15 and Day 21</time_frame>
    <description>Expansion phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(0-24)md based on individual dosing</measure>
    <time_frame>Expansion Phase:Cycle 1 Day1, Day 15 and Day 21</time_frame>
    <description>Expansion phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav(0-24)md based on individual dosing</measure>
    <time_frame>Expansion phase:Cycle 1 Day1, Day 15 and Day 21; Dose escalation phase:Cycle 1 Day1, Day 15 and Day 21</time_frame>
    <description>Expansion phase Dose escalation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2eff,md based on individual dosing</measure>
    <time_frame>Expansion phase:Cycle 1 Day1, Day 15 and Day 21; Dose escalation phase:Cycle 1 Day1, Day 15 and Day 21</time_frame>
    <description>Expansion phase Dose escalation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24)md based on individual dosing</measure>
    <time_frame>Expansion Phase:Cycle 1 Day1, Day 15 and Day 21</time_frame>
    <description>Expansion phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of irinotecan and SN-38</measure>
    <time_frame>Expansion Phase:Cycle 1 Day1, Day 15 and Day 21</time_frame>
    <description>Expansion phase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Pediatric Oncology</condition>
  <arm_group>
    <arm_group_label>Sequential dosing schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concomitant dosing schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation phase: This phase of the study has been completed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (BAY73-4506)</intervention_name>
    <description>Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.</description>
    <arm_group_label>Concomitant dosing schedule</arm_group_label>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Sequential dosing schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine (Cellcristin®)</intervention_name>
    <description>Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.</description>
    <arm_group_label>Concomitant dosing schedule</arm_group_label>
    <arm_group_label>Sequential dosing schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan (Irinotecan Cell pharm®)</intervention_name>
    <description>Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.</description>
    <arm_group_label>Concomitant dosing schedule</arm_group_label>
    <arm_group_label>Sequential dosing schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form by subjects and/or subjects' parents/legal guardians and&#xD;
             age appropriate Assent Form by the subjects obtained before any study specific&#xD;
             procedure&#xD;
&#xD;
          -  Age: from 6 months to less than 18 years old&#xD;
&#xD;
          -  Diagnosis, Dose escalation phase of the study: subjects must have had histologic&#xD;
             verification of solid malignancy at original diagnosis. Subjects with recurrent or&#xD;
             refractory solid tumors are eligible, including primary central nervous system (CNS)&#xD;
             tumors or subjects with known CNS metastases. Subject's current disease state must be&#xD;
             one for which there is no known effective therapy or therapy proven to prolong&#xD;
             survival with an acceptable quality of life. Effective therapy may include surgery,&#xD;
             radiation therapy, chemotherapy or any combination of these modalities.&#xD;
&#xD;
        Dose expansion phase of the study: subjects must have relapsed/refractory RMS or a solid&#xD;
        malignant tumor (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor) in which&#xD;
        treatment with vincristine/irinotecan is considered backbone chemotherapy at relapse and a&#xD;
        scientific rationale to combine vincristine/irinotecan with regorafenib exists.&#xD;
&#xD;
          -  Subjects must have at least one measurable or evaluable lesion according to Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST), version 1.1. For the neuroblastoma&#xD;
             subjects with osteomedullary disease, the SIOPEN (International Society of Pediatric&#xD;
             Oncology Europe Neuroblastoma Group) score will be used. Bone scans (if clinically&#xD;
             indicated) should be obtained ≤12 weeks prior to the start of treatment.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks from the time of signing informed consent/assent.&#xD;
&#xD;
          -  Performance level: Karnofsky ≥ 70% for subjects &gt; 12 years of age or Lansky ≥ 70% for&#xD;
             subjects ≤ 12 years of age&#xD;
&#xD;
          -  Adequate hematological function assessed by the following laboratory requirements&#xD;
             conducted within 7 days before starting study treatment:&#xD;
&#xD;
        Peripheral absolute neutrophil count (ANC): ≥ 1.0 x 10*9/L Platelet count : ≥ 100 x 10*9/L&#xD;
        (transfusion independent) Hemoglobin: ≥ 8.0 g/dL&#xD;
&#xD;
        -Adequate hepatic function defined as:&#xD;
&#xD;
          -  Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 3.0* ULN&#xD;
&#xD;
          -  Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 * ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with regorafenib. Subjects permanently withdrawn from study&#xD;
             participation will not be allowed to re-enter the study.&#xD;
&#xD;
          -  Dose expansion phase of the study only: Subjects with brain tumors or subjects with&#xD;
             known CNS metastases are excluded.&#xD;
&#xD;
          -  Subjects with uncontrolled baseline hypertension higher than Grade 1 NCICTCAE v. 4.0&#xD;
&#xD;
          -  Subjects with evidence or history of disorders of coagulation or thrombosis&#xD;
&#xD;
          -  Cardiac abnormalities and cardiac arrhythmias requiring anti-arrhythmic therapy (beta&#xD;
             blockers or digoxin are permitted)&#xD;
&#xD;
          -  History of organ allograft (including allogeneic bone marrow transplant)&#xD;
&#xD;
          -  Any other malignant disease treated prior to study entry&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Significant gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's&#xD;
             disease or any malabsorption condition&#xD;
&#xD;
          -  Close affiliation with the investigational site, e.g. a close relative of the&#xD;
             investigator or a dependent person (e.g. employee or student of the investigational&#xD;
             site)&#xD;
&#xD;
          -  Unresolved toxicity higher than NCI-CTCAE v. 4.0 Grade 1 attributed to any prior&#xD;
             therapy/procedure (excluding alopecia, chemotherapy-induced ototoxicity, Grade 2&#xD;
             chemotherapy-induced neuropathy and, as per above eligibility criteria, anemia with&#xD;
             hemoglobin ≥ 8 mg/dL and ANC ≥ 1.0 x 10 9/L ).&#xD;
&#xD;
          -  Any other malignant disease treated prior to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric cancer</keyword>
  <keyword>Rhabdomyosarcoma,</keyword>
  <keyword>Ewing sarcoma</keyword>
  <keyword>Hepatoblastoma</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>Wilm's tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

